PADI4 and non-small cell lung carcinoma: Moreover, in another study, PAD4 overexpression inhibited the acquisition of a gefitinib resistance phenotype in NSCLC by inhibiting the Elk-1-mediated EMT, whereas the downregulation of PAD4 had the opposite effect [122].